{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:36:59Z","timestamp":1784770619788,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02383-2","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:43:38Z","timestamp":1778301818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["What\u2019s a migraine day? Towards a consensus definition for clinical care and research \u2013 a Delphi panel-based study"],"prefix":"10.1186","volume":"27","author":[{"given":"Luna","family":"De Loose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Paemeleire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina I.","family":"Deligianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Uluduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erling","family":"Tronvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Schoenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita Sanchez","family":"del Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Ryliskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esme","family":"Ekizoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Petru\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Fronczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Versijpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"1","key":"2383_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","volume":"8","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A et al (2022) Migraine Nat Rev Dis Primers 8(1):2","journal-title":"Migraine Nat Rev Dis Primers"},{"issue":"Suppl 7","key":"2383_CR2","first-page":"1","volume":"8","author":"Classification","year":"1988","unstructured":"Classification (1988) diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classif Comm Int Headache Soc Cephalalgia 8(Suppl 7):1\u201396","journal-title":"Headache Classif Comm Int Headache Soc Cephalalgia"},{"key":"2383_CR3","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1-211","DOI":"10.1177\/0333102417738202"},{"issue":"2","key":"2383_CR4","doi-asserted-by":"publisher","first-page":"333102424123393","DOI":"10.1177\/03331024241233937","volume":"44","author":"PJ Goadsby","year":"2024","unstructured":"Goadsby PJ, Evers S, Gelfand AA, Lipton RB, May A, Pozo-Rosich P et al (2024) International Classification of Headache Disorders-4 -Work in Progress 1. Cephalalgia 44(2):3331024241233937","journal-title":"Cephalalgia"},{"issue":"5","key":"2383_CR5","first-page":"333102423116662","volume":"43","author":"BWH van der Arend","year":"2023","unstructured":"van der Arend BWH, Verhagen IE, van Leeuwen M, van der Arend MQTP, van Casteren DS, Terwindt GM (2023) Defining migraine days, based on longitudinal E-diary data. Cephalalgia 43(5):3331024231166625","journal-title":"Cephalalgia"},{"issue":"10","key":"2383_CR6","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2020) Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia 40(10):1026\u20131044","journal-title":"Cephalalgia"},{"issue":"5","key":"2383_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2018) Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38(5):815\u2013832","journal-title":"Cephalalgia"},{"issue":"11","key":"2383_CR8","doi-asserted-by":"publisher","first-page":"333102425139398","DOI":"10.1177\/03331024251393986","volume":"45","author":"L Loose","year":"2025","unstructured":"Loose L, Paemeleire K, Goadsby PJ, MaassenVanDenBrink A, Versijpt J (2025) What\u2019s a migraine day? Analysis of the variety in the definition of a migraine day across phase III trials with drugs targeting the CGRP pathway. Cephalalgia 45(11):3331024251393986","journal-title":"Cephalalgia"},{"issue":"4","key":"2383_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","volume":"32","author":"F Hasson","year":"2000","unstructured":"Hasson F, Keeney S, McKenna H (2000) Research guidelines for the Delphi survey technique. J Adv Nurs 32(4):1008\u20131015","journal-title":"J Adv Nurs"},{"issue":"7","key":"2383_CR10","doi-asserted-by":"publisher","first-page":"e32829","DOI":"10.1097\/MD.0000000000032829","volume":"102","author":"Z Shang","year":"2023","unstructured":"Shang Z (2023) Use of Delphi in health sciences research: A narrative review. Med (Baltim) 102(7):e32829","journal-title":"Med (Baltim)"},{"key":"2383_CR11","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L et al (2019) The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 95:103208","journal-title":"J Biomed Inform"},{"issue":"2","key":"2383_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381","journal-title":"J Biomed Inform"},{"issue":"3","key":"2383_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1526-4610.2007.00920.x","volume":"48","author":"RW Evans","year":"2008","unstructured":"Evans RW, Seifert T, Kailasam J, Mathew NT (2008) The use of questions to determine the presence of photophobia and phonophobia during migraine. Headache 48(3):395\u2013397","journal-title":"Headache"},{"issue":"4","key":"2383_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1046\/j.1468-2982.1999.019004232.x","volume":"19","author":"Acute treatment of","year":"1999","unstructured":"Acute treatment of (1999) migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K\/Sumatriptan Migraine Study Group. Cephalalgia 19(4):232\u2013240","journal-title":"Cephalalgia"},{"key":"2383_CR15","unstructured":"GlaxoSmithKline (2020) Imitrex (sumatriptan) injection, for subcutaneous use: highlights of prescribing information. Food and Drug Administration"},{"issue":"5","key":"2383_CR16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJM199108013250504","volume":"325","author":"SSIS Group","year":"1991","unstructured":"Group SSIS (1991) Treatment of migraine attacks with sumatriptan. N Engl J Med 325(5):316\u2013321","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1186\/s10194-026-02407-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000}}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02383-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02383-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02383-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:47:30Z","timestamp":1779961650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02383-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2383"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02383-2","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article has been updated to correct the Competing interests statement","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s10194-026-02407-x","URL":"https:\/\/doi.org\/10.1186\/s10194-026-02407-x","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KP received personal fees from Allergan\/AbbVie, Eli Lilly, Lundbeck, Man & Science, Novartis, Pfizer, and Teva as a speaker and\/or advisory board member. CID has received personal fees for lectures\/advisory boards: TEVA, Pfizer, Astra -Zeneca, Orion Pharma, Haleon, Bennett; member at large of European Headache Federation. CL reports, over the last 36 months, personal fees for consulting from AbbVie, Eli Lilly and Company, Pfizer, and Teva Pharmaceuticals, and a research grant from Pfizer. ET has received personal fees for lectures\/advisory boards: Novartis, Eli Lilly, Abbvie, TEVA, Roche, Lundbeck, Pfizer, Biogen, Organon. Consultant for and owner of stocks and IP in Man & Science. Stocks and IP in Nordic Brain Tech. Stocks in Keimon Medical. Non-personal research grants from several sources, including Norwegian Research Council, KlinBeForsk, EU. Commissioned research (non-personal): Lundbeck. Associate Editor Cephalalgia. HS reports receiving personal fees from AbbVie, Lundbeck, P\ufb01zer and Teva. JS received consultancy and advisory support from Man & Science, Abbvie, Novartis, Pfizer, Teva, Lundbeck, Organon, Balancair, and from the National Institute for Health and Disability Insurance (Belgium)MS received personal fees from AbbVie, Organon, Pfizer, and Orion Pharma as a speaker and\/or advisory board member PM serves as Editor-in-Chief of The Journal of Headache and of SN Comprehensive Clinical Medicine. PM did not take part in any review or editorial decision-making process related to this paper. He also serves as an Expert for the European Medicines Agency (EMA). PP-R reports over the last 36 months, fees as a consultant and speaker from AbbVie, Almirall, Dr. Reddy\u2019s, Eli Lilly, Lundbeck, Novartis, Organon, Otsuka Pharmaceuticals, Pfizer, Teva; research grants to her research group: AbbVie, AGAUR, EraNet Neuron, FEDER RIS3CAT, Instituto Investigaci\u00f3n Carlos III, MICINN, Novartis, Teva; funding for clinical trials: AbbVie, Amgen, Eli Lilly, Lundbeck, Merz, Pfizer, Teva; associate editor for Cephalalgia, Neurologia; member of the Clinical Trials Guidelines Committee and Scientific Committee of the International Headache Society; edited Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society; founder of\n                      \n                      , a platform to give information and tools to physicians and people who suffer from migraine and other headaches. KR has received personal fees for lectures\/advisory boards from Novartis, Abbvie, Teva, Lundbeck, Pfizer, Organon, Viatris, Berlin Chemie. EE received honoraria for lectures\/presentations from Pfizer and Neutec. IP serves as member of the Editorial Board of The Journal of Headache and Pain and Head of Imaging Section of the SN Comprehensive Clinical Medicine journal. RF received consultancy fees from Teva, Takeda, Lundbeck, Jazz, Salvia and Centessa; lecture fees from Pharmanovia, Novartis and MedTronic; research support from ZonMw, MedTronic, Takeda, OpZuid, Netherlands Brain Foundation and RiverStyx. PRH reports, unrelated to the current project, honoraria for educational and advisory purposes from Eli Lilly and Company, Allergan, Novartis, Pfizer, Organon and Teva as well as research funding from Eli Lilly and Company, Amgen, and Cellgene\/Bristol Myers Squibb. PRH also serves as a member of the Editorial Board of The Journal of Headache and Pain. UR reports over the last 36 months no personal fees. Institutional fees for consultation from Abbvie, Lundbeck, Pfizer; institutional fees for the generation of educational material and scientific presentations from Abbvie, Lundbeck, Pfizer, Novartis, Lilly and Teva. UR received an institutional research grant from Novartis (Cherub01). PJG reports, over the last 36 months, personal fees for consulting from Aeon Biopharma, Abbvie, Aurene, CoolTech LLC, Dr Reddy\u2019s, Eli-Lilly and Company, Epalex, Ipsen, Kallyope, Linpharma, Lundbeck, Orion Pharma, Pfizer, PureTech Health LLC, Satsuma, Shiratronics, Teva Pharmaceuticals, and Vial, and personal fees for advice through Gerson Lehrman Group, Guidepoint, SAI Med Partners, Vector Metric, and fees for educational materials from CME Outfitters and WebMD, and publishing royalties or fees from Massachusetts Medical Society, Oxford University Press, UptoDate and Wolters Kluwer. AMvdB received research grants and\/or consultation fees from AbbVie, Amgen\/Novartis, Eli Lilly, Lundbeck, Manistee, Organon, Pfizer, Satsuma, Teva, and Tonix. JV received personal fees and nonfinancial support from Teva, Pfizer and Medtronic, personal fees from Novartis and Lundbeck, and grants and nonfinancial support from Allergan\/AbbVie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}